Fortress Biotech Inc (FBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $62.70M
Last updated: Nov 17, 2026 at 11:04 AM ET
Fortress Biotech Inc (FBIO) P/E Ratio & Valuation History
Fortress Biotech (FBIO) trades at 0.7x trailing earnings and 0.8x sales. Its P/B of 0.4x is below its 5-year median of 1.8x. Its forward P/E is 1.2x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 41.7% lower over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 0.7x |
| Forward P/E | 1.2x |
| Price to sales | 0.8x |
| Price to book | 0.4x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/B is 85.2% below 2.7x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 0.4x | 1.8x | 2.7x |
Valuation History
Over the 7 of the 10 year ends shown that have a P/S, its P/S ranged from 0.7x in 2024 to 5.0x in 2020.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $3.66 | N/A | 2.0x | 20.5x |
| 2024 | $2.03 | N/A | 0.7x | 1.8x |
| 2023 | $3.01 | N/A | N/A | 1.0x |
| 2022 | $9.82 | N/A | N/A | 11.3x |
| 2021 | $37.48 | 9.8x | 3.1x | 2.2x |
| 2020 | $47.53 | N/A | 5.0x | 2.5x |
| 2019 | $38.53 | N/A | N/A | 5.8x |
| 2018 | $12.89 | N/A | 1.4x | 20.0x |
| 2017 | $59.82 | N/A | 1.2x | 3.1x |
| 2016 | $40.48 | N/A | 2.4x | 2.8x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About FBIO
What is FBIO's forward P/E ratio?
Fortress Biotech has a forward P/E ratio of 1.2x.
Is FBIO stock overvalued?
GNG's valuation label for FBIO is Undervalued.
What is FBIO's price to sales ratio?
Fortress Biotech has a price to sales ratio of 0.8x.
FBIO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors